RSK4 促进食管鳞状细胞癌中的巨噬细胞募集和 M2 极化。
RSK4 promotes the macrophage recruitment and M2 polarization in esophageal squamous cell carcinoma.
机构信息
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University, Xi'an, China; Department of Pathology, Baotou Medical college, Baotou, Inner Mongolia Autonomous Region, China.
Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
出版信息
Biochim Biophys Acta Mol Basis Dis. 2024 Mar;1870(3):166996. doi: 10.1016/j.bbadis.2023.166996. Epub 2023 Dec 22.
High infiltration of tumor-associated macrophages (TAMs) participates in host immunity and tumor progression in patients with esophageal squamous cell carcinoma (ESCC). Ribosomal s6 kinase 4 (RSK4) has been shown to be aberrantly overexpressed in ESCC. The role of RSK4 in cytokine secretion and its impact on macrophage recruitment and M2 polarization remains unclear. Therefore, a thorough understanding of RSK4 is needed to expand our knowledge of its therapeutic potential. Herein, RSK4 expression in human ESCC tissues and a xenograft mouse model was positively correlated with high infiltration of M0 and M2 macrophages which is positively associated with unfavorable overall survival outcomes and treatment resistance in patients with ESCC. In vitro experiments revealed that RSK4 derived from ESCC cells promoted macrophage recruitment and M2 polarization by enhancingsoluble intercellular adhesion molecule-1 (sICAM-1) secretion via direct and indirect STAT3 phosphorylation. Furthermore, RSK4-induced macrophages enhanced tumor proliferation, migration, and invasion by secreting C-C motif chemokine ligand 22 (CCL22). We further showed that patients with elevated CD68 and CD206 expression had unfavorable overall survival. Collectively, these results demonstrate that RSK4 promotes the macrophage recruitment and M2 polarization by regulating the STAT3/ICAM-1 axis in ESCC, influencing tumor progression primarily in a CCL22-dependent manner. These data also offer valuable insights for developing novel agents for the treatment of ESCC.
肿瘤相关巨噬细胞(TAMs)的高浸润参与了食管鳞状细胞癌(ESCC)患者的宿主免疫和肿瘤进展。核糖体 S6 激酶 4(RSK4)已被证明在 ESCC 中异常过表达。RSK4 在细胞因子分泌中的作用及其对巨噬细胞募集和 M2 极化的影响尚不清楚。因此,需要对 RSK4 进行深入了解,以扩大我们对其治疗潜力的认识。在此,RSK4 在人 ESCC 组织和异种移植小鼠模型中的表达与 M0 和 M2 巨噬细胞的高浸润呈正相关,而 M0 和 M2 巨噬细胞的高浸润与 ESCC 患者总体生存结局不良和治疗耐药性相关。体外实验表明,ESCC 细胞来源的 RSK4 通过直接和间接磷酸化 STAT3 增强可溶性细胞间黏附分子-1(sICAM-1)的分泌,促进巨噬细胞募集和 M2 极化。此外,RSK4 诱导的巨噬细胞通过分泌 C-C 基序趋化因子配体 22(CCL22)增强肿瘤增殖、迁移和侵袭。我们进一步表明,CD68 和 CD206 表达升高的患者总体生存不良。综上所述,这些结果表明 RSK4 通过调节 ESCC 中的 STAT3/ICAM-1 轴促进巨噬细胞募集和 M2 极化,主要以 CCL22 依赖的方式影响肿瘤进展。这些数据还为开发治疗 ESCC 的新型药物提供了有价值的见解。